Drugs in Dev. Infections and Infectious Diseases
Phase II/ Phase III
India 
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Russian Direct Investment Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's and RDIF Commence Clinical Trials for Sputnik V Vaccine in India
Details : After obtaining the requisite clearance from the Central Drugs Laboratory, Dr. Reddy's Laboratories and RDIF have begun adaptive phase 2/3 clinical trials for the Sputnik V vaccine in India. The trial is a multicenter and randomised controlled safety and...
Product Name : Sputnik V
Product Type : Vaccine
Upfront Cash : Inapplicable
December 01, 2020
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Russian Direct Investment Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Russian Direct Investment Fund | JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gam-COVID-Vac is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Russian Direct Investment Fund | JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Panel May Review Gennova's mrna Omicron Booster Vaccine
Details : Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gennova Biopharma Submits Final Vaccine Trial Data to Regulator
Details : Company has conducted phase-2/3 trials of vaccine candidates to evaluate its safety, immunogenicity and tolerability on 4,000 participants, for first indigenously developed HGCO19, mRNA vaccine for Covid-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 12, 2022
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
India's First Homegrown mRNA COVID-19 Vaccine Currently Under Final Clinical Trial Stages: Govt
Details : Gennova's synthetic, self-replicating India's first homegrown mRNA vaccine is in Phase III Clinical Trials for the treatment of COVID-19 is currently under final clinical trial stages. .
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
New Covid vaccine: Bio E May submit Corbevax Trial Data This Month
Details : Corbevax is in phase-3 trials and likely to complete all the studies by end of November which is when company is expecting licence. The licence for children should follow one month later.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
November 09, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Corbevax is an RBD protein based sub-unit vaccine against the coronavirus infections. Corbevax is based on a protein antigen technology that binds to the Angiotensin Converting Enzyme-2 (ACE2) receptor on the host cell membrane.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biological E's Corbevax Gets Nod for Phase 2/3 Trials on Those aged 5-18
Details : Corbevax is an RBD protein sub-unit vaccine that has been developed with supported from the Department of Biotechnology and its PSU Biotechnology Industry Research Assistance Council (BIRAC).
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
September 03, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBV87,Aluminium Hydroxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : The International Vaccine Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
IVI and BBIL Launch Global Chikungunya Vaccine Phase II/III trial in Costa Rica
Details : BBIL’s BBV87 vaccine is an inactivated whole virion vaccine based on strain derived from an East, Central, South African (ECSA) genotype. IVI is advancing clinical development of BBV87 to evaluate safety and immunogenicity of 2-dose regimen of BBV87 Ch...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 24, 2021
Lead Product(s) : BBV87,Aluminium Hydroxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : The International Vaccine Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
